Cafelkibart’s entry into phase 3 is of note to Coherus.
ApexOnco Front Page
Recent articles
The company is starting four new pivotal trials this year.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A single-arm trial was enough for J&J’s Inlexzo nod.
ESMO and the Triple Meeting approach.
